Arovella Therapeutics (FRA:E4NA) Total Stockholders Equity : €6.93 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Arovella Therapeutics Total Stockholders Equity?

Arovella Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2024 was €6.93 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Arovella Therapeutics's Book Value per Share for the quarter that ended in Jun. 2024 was €0.01. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Arovella Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2024 was 0.00.

Arovella Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Arovella Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics Total Stockholders Equity Chart

Arovella Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Stockholders Equity

Get a 7-Day Free Trial

2.53

5.70

5.06

2.34

6.93

Arovella Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Stockholders Equity	Get a 7-Day Free Trial															5.06	2.71	2.34	1.92	6.93

Arovella Therapeutics (FRA:E4NA) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Arovella Therapeutics's Book Value per Share for the quarter that ended in Jun. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(6.926	-	0)	/	1050.56
	=	0.01

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Arovella Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	6.926
	=	0.00

Arovella Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Arovella Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Arovella Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (FRA:E4NA) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

ALA:Australia

Address

62 Lygon Street, Level 3, Carlton, WA, AUS, 3053

Website

https://www.arovella.com

Arovella Therapeutics Ltd is a biotechnology company focused on developing therapies to treat human diseases. Its two focus areas are oncology and conditions that impact the central nervous system. The company's principal activity is the pharmaceutical development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer.

Arovella Therapeutics Headlines

No Headlines